Pasar al contenido principal

BIOCONSERVANTES BASADOS EN PROTEINAS FAGICAS: PRODUCCION OPTIMIZADA PARA LA INDUSTRIA ALIMENTARIA

PID2019-105311RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Developing Diagnostic and Therapeutic Approaches to Bacterial Infections for a New Era: Implications of Globalization

  • Fernández Llamas, Lucía
  • Cima-Cabal, María Dolores
  • Duarte, Ana Catarina
  • Rodríguez González, Ana
  • García Suárez, María Pilar
  • García-Suárez, María del Mar
© 2020 by the authors., In just a few months, the current coronavirus pandemic has exposed the need for a more global approach to human health. Indeed, the quick spread of infectious diseases and their unpredictable consequences, in terms of human lives and economic losses, will require a change in our strategy, both at the clinical and the research level. Ultimately, we should be ready to fight against infectious diseases affecting a huge number of people in different parts of the world. This new scenario will require rapid, inexpensive diagnostic systems, applicable anywhere in the world and, preferably, without the need for specialized personnel. Also, treatments for these diseases must be versatile, easily scalable, cheap, and easy to apply. All this will only be possible with joint support of the governments, which will have to make the requirements for the approval of new therapies more flexible. Meanwhile, the pharmaceutical sector must commit to prioritizing products of global interest over the most profitable ones. Extreme circumstances demand a vehement response, and any profit losses may well pay dividends going forward. Here, we summarize the developing technologies destined to face the current and future health challenges derived from infectious diseases and discuss which ones have more possibilities of being implemented., This research was funded by grants UNIR BIO0036; Santander-Crue grant (PN036-2022); Innovative Training Networks (ITN) Marie Skłodowska-Curie Actions H2020-MSCA-ITN-2018. Reference 813439; PID2019-105311RB-I00 (MICIU/AEI/FEDER, UE, Spain; PCIN-2017-001 (AEI/FEDER, UE, Spain); IDI/2018/000119 (Program of Science, Technology and Innovation 2018–2020 and FEDER EU funds, Principado de Asturias, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gram-Positive Pneumonia: Possibilities Offered by Phage Therapy

  • Fernández Llamas, Lucía
  • Cima-Cabal, María Dolores
  • Duarte, Ana Catarina
  • Rodríguez González, Ana
  • García-Suárez, María del Mar
  • García Suárez, María Pilar
Pneumonia is an acute pulmonary infection whose high hospitalization and mortality rates can, on occasion, bring healthcare systems to the brink of collapse. Both viral and bacterial pneumonia are uncovering many gaps in our understanding of host–pathogen interactions, and are testing the effectiveness of the currently available antimicrobial strategies. In the case of bacterial pneumonia, the main challenge is antibiotic resistance, which is only expected to increase during the current pandemic due to the widespread use of antibiotics to prevent secondary infections in COVID-19 patients. As a result, alternative therapeutics will be necessary to keep this disease under control. This review evaluates the advantages of phage therapy to treat lung bacterial infections, in particular those caused by the Gram-positive bacteria Streptococcus pneumoniae and Staphylococcus aureus, while also highlighting the regulatory impediments that hamper its clinical use and the difficulties associated with phage research, This research was funded by grants UNIR BIO0036; Santander-Crue grant (PN036-2022); Innovative Training Networks (ITN) Marie Skłodowska-Curie Actions H2020-MSCA-ITN-2018. Reference 813439; PID2019-105311RB-I00 (MICIU/AEI/FEDER, UE, Spain; PCIN-2017-001 (AEI/FEDER, UE, Spain); IDI/2018/000119 (Program of Science, Technology and Innovation 2018–2020 and FEDER EU funds, Principado de Asturias, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Combined use of bacteriocins and bacteriophages as food biopreservatives. A review

  • Rendueles Martínez, Claudia
  • Duarte, Ana Catarina
  • Escobedo, Susana
  • Fernández Llamas, Lucía
  • Rodríguez González, Ana
  • García Suárez, María Pilar
  • Martínez Fernández, Beatriz
Throughout history, humans have consistently developed strategies to prevent food-associated illnesses. However, despite our multiple technological advances, food safety is still an issue of concern. Moreover, there is a demand for gaining access to less processed and naturally preserved food. Food biopreservation, understood as the use of natural antimicrobials already present in food with a long history of safe consumption, is seen as a plausible strategy to reduce the intensity of current preservation technologies (e.g., presence of chemically synthesized food preservatives). In that sense, the combined use of several antimicrobial strategies, known as hurdle technology, has been often chosen as a means to improve the efficacy of food biopreservation. This review intends to summarize the most recent examples of the combined use of bacteriocins and bacteriophages to extend food shelf-life and reduce the risks associated with the presence of foodborne bacteria along the food chain. However, while the efficacy of bacteriocins has been extensively documented, bacteriophages have only started to be assessed as potential food biopreservatives more recently. Within this context, we would like to consider whether these two types of natural antimicrobials would help each other to overcome bottlenecks in food biopreservation., Research at the DairySafe group is funded by grant PID2019-105311RB-I00 (MCIN/ AEI/10.13039/501100011033) to P.G. and A.R., grant PID2020-119697RB-I00 (MCIN/ AEI/10.13039/501100011033) to B.M. and A.R and grant AYUD/2021/52120 (Program of Science, Technology and Innovation 2021–2023 (FICYT and FEDER EU), Principado de Asturias, Spain). C.R is a fellow of the program “Ayudas Severo Ochoa” of the Principado de Asturias, Spain (BP20 006). A.C.D. is a fellow from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 813439., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting biofilms using phages and their enzymes

  • Azeredo, Joana
  • García Suárez, María Pilar
  • Drulis-Kawa, Zuzanna
The complex biofilm architecture composed of extracellular polymeric structures (EPS) provides a protective shield to physiologically diverse bacterial cells immersed in its structure. The evolutionary interplay between bacteria and their viruses (phages) forced the latter ones to develop specific strategies to overcome the biofilm defensive barriers and kill sessile cells. Phages are equipped with a wide panel of enzyme-degrading EPS macromolecules which together are powerful weapons to combat biofilms. Antibiofilm performance can be achieved by combining phages or phage-borne enzymes with other antimicrobials such as antibiotics. Nevertheless, a variety of enzymes encoded in phage genomes still need to be explored. To advance in biofilm control strategies we must deepen the understanding of the biofilm biology itself, as well as discover and better exploit the unlimited antibacterial potential of phages., JA was supported by the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UIDB/04469/2020 unit. PG was supported by grants from Innovative Training Networks (ITN) Marie Skłodowska-Curie Actions H2020-MSCA-ITN-2018. Reference 813439, and PID2019-105311RB-I00 (MICIU/AEI/FEDER, UE, Spain). ZDK was supported by the National Science Centre of Poland (Narodowe Centrum Nauki), grant numbers 2016/21/B/NZ6/01157 and 2017/26/M/NZ1/00233.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Análisis de la efectividad de la endolisina LysRODI para eliminar Staphylococcus aureus en leche

  • Fernández Llamas, Lucía
  • Rodríguez González, Ana
  • García Suárez, María Pilar
Resumen del trabajo presentado en el XXVIII Congreso Nacional de la Sociedad Española de Microbiología, celebrado de forma virtual del 28 de junio al 2 de julio de 2021, Staphylococcus aureus es uno de los principales microorganismos responsables de la mastitis bovina, enfermedad que da lugar a pérdidas económicas en el sector lácteo. Además, este patógeno puede también llegar a contaminar la leche, derivando así en un problema de salud humana. Recientemente, se está explorando el uso de bacteriófagos, virus que infectan bacterias, y sus proteínas derivadas como una alternativa y/o complemento a los antibióticos y desinfectantes convencionales. LysRODI es una endolisina de origen fágico con actividad peptidoglicano hidrolasa que, cuando se administra desde el exterior, degrada el peptidoglicano de la pared celular bacteriana, lo que acaba desembocando en la lisis de la célula. En trabajos anteriores ya se había demostrado su efectividad frente a biofilms formados por este microorganismo. Este trabajo explora la eficacia de esta proteína para el tratamiento de leche contaminada con S. aureus. Así, se estudió el efecto del tratamiento con LysRODI a distintos tiempos de incubación y a distintas temperaturas (25ºC y 37ºC). También se analizó la actividad de este enzima frente a distintas cepas de esta bacteria y distintos niveles de contaminación bacteriana. Los resultados mostraron la posibilidad de utilizar esta proteína para reducir el número de células de S. aureus en leche, si bien la eficacia del tratamiento depende de las condiciones ambientales y del grado de contaminación. Por tanto, será importante estudiar en un futuro la posible combinación de LysRODI con otros antimicrobianos para conseguir maximizar la eliminación de S. aureus., PID2019-105311RB-I00 (MICIU/AEI/FEDER, UE, Spain)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Actividad estafilocócica de las endolisinas LysRODI y LysRODI¿Ami en leche y queso fresco

  • Agún, Seila
  • Fernández Llamas, Lucía
  • Rodríguez González, Ana
  • García Suárez, María Pilar
Trabajo presentado en la VII Reunión Red Española de Bacteriófagos y Elementos Transductores - RED FAGOMA, celebrada en Trujillo, Cáceres (España), del 26 al 28 de octubre de 2022
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deletion of the amidase domain of endolysin LysRODI enhances antistaphylococcal activity in milk and during fresh cheese production

  • Agún, Seila
  • Fernández Llamas, Lucía
  • Rodríguez González, Ana
  • García Suárez, María Pilar
Milk contamination with Staphylococcus aureus can lead to food poisoning in consumers. One strategy to minimize this risk is the use of phage-derived lysins, which are innocuous for humans and do not readily select for resistant variants. However, it remains necessary to find new candidate lysins and define the conditions for their utilization. This study compares the potential of LysRODI and its derivative LysRODIΔAmi (lacking the amidase domain), which displays high activity and storage stability, to successfully decrease staphylococcal contamination in milk under different conditions. Our results show that the engineered protein is more efficacious than the parent endolysin in practically all cases. For instance, while LysRODI only decreased the number of cells by 1–2 log units in different types of commercial milk and contamination levels, the chimeric lysin eliminated them below detection. Also, LysRODIΔAmi was more active against four strains with varying degrees of susceptibility. Regarding incubation temperature, both proteins were faster at 32 °C and 37 °C. Significantly, the engineered lysin eliminated detectable contamination in just 15 min. Finally, LysRODIΔAmi proved very successful at reducing staphylococcal contamination below detection during lab-scale fresh cheese production by enzymatic coagulation. Our data show that LysRODIΔAmi is a promising candidate for biocontrol in milk., This work was funded by grants PID2019-105311 RB-I00 (MICIU/AEI/FEDER, EU, Spain501100011033) to P.G. and A.R, and AYUD/2021/52120 (Program of Science, Technology and Innovation, 2021–2023 and FEDER EU, Principado de Asturias, Spain). S.A. has an FPI fellowship (Ministry of Science and Innovation, Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impact of the calcium concentration on the efficacy of phage phiIPLA-RODI, LysRODI¿Ami and nisin for the elimination of Staphylococcus aureus during lab-scale cheese production

  • Youssef, Olivia
  • Agún, Seila
  • Fernández Llamas, Lucía
  • Khalil, Samy A.
  • Rodríguez González, Ana
  • García Suárez, María Pilar
Staphylococcus aureus is a Gram-positive human opportunistic pathogen that may also cause food poisoning because of the ability of some strains to produce heat stable enterotoxins that can persist in food even after the pathogen is successfully eliminated. In this context, biopreservation may be a forward-looking strategy to help eliminate staphylococcal contamination in dairy products by using natural compounds. However, these antimicrobials exhibit individual limitations that may be overcome by combining them. This work investigates the combination of a virulent bacteriophage, phiIPLA-RODI, a phage-derived engineered lytic protein, LysRODIΔAmi, and the bacteriocin nisin for the elimination of S. aureus during lab-scale cheese production at two CaCl2 concentrations (0.2 % and 0.02 %), and subsequent storage at two different temperatures (4 °C and 12 °C). In most of the assayed conditions, our results demonstrate that the combined action of the antimicrobials led to a greater reduction of the pathogen population than the compounds individually, albeit this effect was additive and not synergistic. However, our results did show synergy between the three antimicrobials for reducing the bacterial load after 14 days of storage at 12 °C, temperature at which there is growth of the S. aureus population. Additionally, we tested the impact of the calcium concentration on the activity of the combination treatment and observed that higher CaCl2 levels led to a notable increase in endolysin activity that allowed the utilization of approximately 10-times less protein to attain the same efficacy. Overall, our data show that the combination of LysRODIΔAmi with nisin and/or phage phiIPLA-RODI, and an increase in the calcium concentration are successful strategies to decrease the amount of protein required for the control of S. aureus contamination in the dairy sector with a low potential for resistance selection, thereby reducing costs., This work was funded by grants PID2019-105311RB-I00 (MICIU/AEI/FEDER, UE, Spain) to P.G. and A.R., and AYUD/2021/52120 (Program of Science, Technology and Innovation 2021–2023, FICYT and FEDER EU, Principado de Asturias, Spain). S.A. has an FPI fellowship (Ministry of Science and Innovation, Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prevalence of virulence- and antibiotic resistance-associated genotypes and phenotypes in Staphylococcus aureus strains from the food sector compared to clinical and cow mastitis isolates

  • Jurado, Andrea
  • Fernández Llamas, Lucía
  • Rodríguez González, Ana
  • García Suárez, María Pilar
Infections by the pathogen Staphylococcus aureus currently represent one of the most serious threats to human health worldwide, especially due to the production of enterotoxins and the ability to form biofilms. These structures and the acquisition of antibiotic resistance limit the action of antibiotics and disinfectants used to combat this microorganism in the industry and the clinic., This work was funded by grants MCIN/AEI/10.13039/501100011033/FEDER, UE, grant number PID2022-140988OB-I00, awarded to PG and LF, PID2019-105311RB-I00 (MICIU/AEI/FEDER, UE, Spain) to PG and AR, and AYUD/2021/52120 (Program of Science, Technology and Innovation 2021-2023, FICYT and FEDER EU, Principado de Asturias, Spain). AJ was awarded a JAE-Intro Scholarship (CSIC, Spain) and is currently a fellow of the program “Ayudas Severo Ochoa” of the Principality of Asturias., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synergistic removal of Staphylococcus aureus biofilms by using a combination of phage Kayvirus rodi with the exopolysaccharide depolymerase Dpo7

  • Duarte, Ana Catarina
  • Fernández Llamas, Lucía
  • Jurado, Andrea
  • Campelo, Ana Belén
  • Shen, Yang
  • Bellón Rodríguez, Ana
  • García Suárez, María Pilar
Bacteriophages have been shown to penetrate biofilms and replicate if they find suitable host cells. Therefore, these viruses appear to be a good option to tackle the biofilm problem and complement or even substitute more conventional antimicrobials. However, in order to successfully remove biofilms, in particular mature biofilms, phages may need to be administered along with other compounds. Phage-derived proteins, such as endolysins or depolymerases, offer a safer alternative to other compounds in the era of antibiotic resistance., This work was funded by grants PID2022-140988OB-I00 (MCIN/AEI/10.13039/501100011033/FEDER) awarded to PG and LF, PID2019-105311RB-I00 (MICIU/AEI/FEDER, UE, Spain) to PG and AR, and AYUD/2021/52120 (Program of Science, Technology and Innovation 2021-2023, FICYT and FEDER EU, Principado de Asturias, Spain). Moreover, this work was co-funded by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant Agreement No. 813439 (Break Biofilms). A.J. was awarded a JAE-Intro Scholarship (CSIC, Spain) and is currently a fellow of the program “Ayudas Severo Ochoa” of the Principality of Asturias., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Phage lytic proteins: a natural approach to agro-food safety

  • Agún, Seila
  • Fernández Llamas, Lucía
  • Rodríguez González, Ana
  • García Suárez, María Pilar
Sustainability is a leading trend in the context of food production. Additionally, consumers increasingly demand safer and less-processed products. Among the different technologies used to maintain the quality and extend the shelf-life of fresh and minimally-processed food, natural antimicrobial agents offer a promising strategy to replace conventional compounds. In this regard, phage lytic proteins or lysins, such as endolysins and virion-associated peptidoglycan hydrolases (VAPGHs), have been proposed as a viable option for the avoidance and elimination of undesirable bacteria within the food production chain. Even when applied exogenously, these proteins can degrade the bacterial cell wall maintaining their lytic activity. This feature, alongside their modular structure, which can be exploited for bioengineering, provides significant biotechnological potential. However, despite the promising properties of lysins, the main obstacle for their commercialization is the limited legal information regulating their use. This challenge underscores the need to navigate complex regulatory pathways. The primary objective of this review is to address this crucial gap and summarize the many prospective applications of endolysins during the different stages of food production. By doing so, we aim to provide clarity and insight into the regulatory challenges that must be overcome for the successful utilization of lysins., This work was funded by grants PID2019-105311RB-I00 (MICIU/AEI/FEDER, UE, Spain) to P.G. and A.R., and AYUD/2021/52120 (Program of Science, Technology and Innovation 2021-2023 and FEDER EU, Principado de Asturias, Spain). S.A. has an FPI fellowship (Ministry of Science and Innovation, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Milk promotes the development of complex, protein-rich biofilms in Staphylococcus aureus and limits the efficacy of phage-based eradication strategies

  • Agún, Seila
  • Fernández Llamas, Lucía
  • Rodríguez González, Ana
  • García Suárez, María Pilar
The ability of Staphylococcus aureus to establish strong biofilms in milk poses a threat to consumers’ health and a challenge for the dairy industry. Indeed, biofilms are the main bacterial reservoir along the food chain. Here, we evaluate the efficacy of phage Kayvirus rodi and lytic protein LysRODIΔAmi for combating biofilm formation on polystyrene and stainless steel surfaces submerged in UHT skim milk compared to culture medium. Biofilms grown in milk exhibited a denser and more complex matrix, mainly composed of proteins, presumably casein. Additionally, cells exhibited an adaptive transcriptional response intended to metabolize lactose and to increase biofilm formation. These changes in metabolism, matrix composition and structure conferred milk-grown biofilms a higher resistance to both LysRODIΔAmi (4 μM) and phage Kayvirus rodi (10<sup>8</sup> PFU/ml) individual and combined treatments, although the combination was more efficacious. Both antimicrobials were more successful at biofilm inhibition, exhibiting a synergistic interaction when used together. Unexpectedly, the bacteriophage treatment displayed enhanced efficacy in milk compared to fresh medium, likely due to the buffering capacity and ions in milk, which help stabilize pH and promote phage stability. Our results demonstrate the importance of testing antimicrobials under conditions that reflect the real-life application as much as possible., This work was funded by grants PID2022-140988OB-I00 (MCIN/AEI/10.13039/501100011033/FEDER, UE) to P.G and L.F, PID2019-105311RB-I00 (MICIU/AEI/FEDER, UE, Spain) to P.G. and A.R.; and AYUD/2021/52120 (Program of Science, Technology and Innovation 2021–2023 and FEDER, EU, Principado de Asturias, Spain). S.A. has an FPI fellowship (Ministry of Science and Innovation, Spain). DairySafe group is part of the Spanish Network of Bacteriophages and Transducer Elements-FAGOMA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Isolation of a new myovirus, phiIPLA-LAVI, with potential for biocontrol application in the dairy industry

  • Alonso, Ana Magdalena
  • Braz, Márcia
  • Ruffo, Valeria
  • Agún, Seila
  • Calvo, Rosana
  • García Suárez, María Pilar
  • Fernández Llamas, Lucía
Effective biocontrol of Staphylococcus aureus in foods requires the use of new antimicrobials, such as bacteriophages, especially due to the emergence of multidrug-resistant strains. This study reports the isolation of a new myovirus, phiIPLA-LAVI, from a sewage sample. Despite its specificity against S. aureus, the host range of this phage is quite broad within its target species, infecting 83.7 % of the 43 strains tested. phiIPLA-LAVI has a circular genome, approximately 132,180 bp in size, and belongs to the Herelleviridae family, representing a new species within the Silviavirus genus. Furthermore, no genes involved in lysogeny, virulence or antibiotic resistance were detected, making it potentially safe to use in phage therapy or biocontrol. Compared to other Staphylococcus phages, phiIPLA-LAVI exhibited a similar burst size (25 PFU/infected cell), but a shorter infection cycle (25 min), suggesting a faster antimicrobial action. Additionally, this phage displayed stability at temperatures of up to 60 °C and pH values between 4 and 11. phiIPLA-LAVI demonstrated the ability to kill cells in dairy matrices like milk, enzymatically-coagulated cheese and acid-coagulated cheese. The latter would be facilitated by its high stability at the pH values found during fermentation (between 4 and 7). This makes phiIPLA-LAVI more suitable than those staphylophages (like phiIPLA-RODI) that are significantly inactivated at a pH of 4. Besides reducing the S. aureus population in milk during cheese manufacturing, this phage displayed limited, but promising, potential for preventing and eliminating biofilms grown in milk, thereby reducing the ability of this pathogen to persist on dairy surfaces., This work was funded by grants PID2022-140988OB-I00 (MCIN/AEI/10.13039/501100011033/FEDER, UE) to P.G and L.F, PID2019-105311RB-I00 (MICIU/AEI/FEDER, UE, Spain) to P.G. A.M. and S.A. have FPI fellowships (Ministry of Science and Innovation, Spain). DairySafe group is part of the Spanish Network of Bacteriophages and Transducer Elements-FAGOMA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Broad-host-range Kayvirus phages preferentially infect Staphylocococcus aureus cells with β-glycosylated WTA, the most common bacterial form in the human host

  • Jurado, Andrea
  • Gómez-Cambronero, Carlos
  • Rodríguez González, Ana
  • López, Daniel
  • García, Pilar
  • Fernández, Lucía
[Data availability statement] RNA-Seq data have been deposited in NCBI’s Gene Expression Omnibus (GEO) under the GEO series accession number GSE290813., [Objectives] In Staphylococcus aureus, WTA glycosylation participates in the interaction with the immune system and bacteriophage adsorption. Indeed, virulent phages with podovirus morphology and some myoviruses require β-glycosylation (catalized by TarS), and are hindered by α-glycosylation (carried out by TarM) of WTA. In contrast, other myophages, like phiIPLA-RODI and phage K, exhibit a broad-host range and infect strains without either glycosylation according to the spot test. Here, we set out to determine the impact of glycosylation type on susceptibility to the Kayvirus phiIPLA-RODI., [Methods] Phage susceptibility was tested through different assays and the impact of capsule production and WTA glycosylation was studied through genome and mutant analyses., [Results] We demonstrate that phages K and phiIPLA-RODI, despite not requiring WTA glycosylation, are both significantly more efficient at infecting strains with tarS-mediated modifications. Moreover, presence of tarM correlates with decreased susceptibility to phiIPLA-RODI, especially in strains lacking an intact capsule. Besides confirming that mutations in the quorum-sensing system Agr confer reduced susceptibility to some phages, we also identified the alternative sigma factor SigB as an additional regulator of phage infectivity. While Agr controls transcription of tarM, SigB exerts this role by modulating tarS expression., [Conclusions] Our results suggest that the majority of known virulent phages infecting S. aureus have evolved to maximize their chances of infecting this pathogen in the mammalian host. While this is good news from the perspective of phage therapy, the potential impact of altering the balance between phage and host by exposing cells to high doses of phages must be examined., This work was funded by grants PID2022-140988OB-I00 (MCIN/AEI/10.13039/501100011033/FEDER, UE) to P.G and L.F, PID2019-105311RB-I00 (MICIU/AEI/FEDER, UE, Spain) to P.G. and A.R.; and AYUD/2021/52120 (Program of Science, Technology and Innovation 2021-2023 and FEDER EU, Principado de Asturias, Spain). A.J. has a Severo Ochoa fellowship (Principado de Asturias, Spain) and received funding from the Spanish Society of Microbiology under the Cesar Nombela Mobility Program. The DairySafe group is part of the Spanish Network of Bacteriophages and Transducer Elements-FAGOMA. C.C.G.-C. is staff hired under the Generation D initiative, promoted by Red.es, an organisation attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union's Next Generation funds (grant MMT24-FAGOTECA-01)., Peer reviewed